Published in Ann Oncol on August 01, 2009
Racial differences in survival after surgical treatment for melanoma. Ann Surg Oncol (2011) 0.95
Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle (2012) 0.89
Primary malignant melanoma of the stomach: report of a case. Surg Today (2011) 0.86
Identifying Persons at Highest Risk of Melanoma Using Self-Assessed Risk Factors. J Clin Exp Dermatol Res (2011) 0.85
TRPA1 is functionally expressed in melanoma cells but is not critical for impaired proliferation caused by allyl isothiocyanate or cinnamaldehyde. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.79
The pursuit of oncotargets through understanding defective cell regulation. Oncotarget (2010) 0.78
Surgery of primary melanomas. Cancers (Basel) (2010) 0.77
Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. Oncoimmunology (2016) 0.75
A Case of Malignant Melanoma with In-Transit Metastasis That Responded to Intravenous Infusion of Interferon-β. Case Rep Dermatol (2014) 0.75
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol (2002) 3.05
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol (2009) 2.63
Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol (2002) 2.57
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet (2001) 2.40
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol (1994) 2.10
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev (2003) 2.08
Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol (1998) 1.82
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol (2002) 1.38
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol (2002) 1.15
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol (2010) 1.14
Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol (2002) 1.10
Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol (2007) 0.99
Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer (2001) 0.93
The role interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer (2001) 0.90
Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol (2003) 0.89
Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet (1998) 4.46
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 3.97
Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet (2000) 2.72
Severe sunburn and subsequent risk of primary cutaneous malignant melanoma in scotland. Br J Cancer (1982) 2.49
Reasons for poor prognosis in British patients with cutaneous malignant melanoma. Br Med J (Clin Res Ed) (1986) 2.49
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet (2001) 2.40
Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol (1997) 2.38
Experience of a public education programme on early detection of cutaneous malignant melanoma. BMJ (1988) 2.36
Malignant melanoma in Scotland 1979-1983. Lancet (1985) 2.30
CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood (1996) 2.30
Epidemiology of invasive cutaneous melanoma. Ann Oncol (2009) 2.21
Factors involved in presentation of older people with thick melanoma. Med J Aust (1998) 2.20
BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. Br J Dermatol (2013) 2.17
Presentation and surgical management of bronchogenic and esophageal duplication cysts in adults. Chest (1998) 2.07
Nicotine, alcohol and drug dependence and psychiatric comorbidity. Results of a national household survey. Br J Psychiatry (2001) 2.01
Characterization of mononuclear effector cells in human blood. Clin Exp Immunol (1976) 1.96
Methadone treatment practices and outcome for opiate addicts treated in drug clinics and in general practice: results from the National Treatment Outcome Research Study. Br J Gen Pract (1999) 1.95
Effects of cigarette smoking on the immune system. Follow-up studies in normal subjects after cessation of smoking. Med J Aust (1983) 1.94
Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol (2000) 1.92
Preseason hamstring muscle weakness associated with hamstring muscle injury in Australian footballers. Am J Sports Med (1997) 1.90
Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res (1999) 1.88
Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) (1986) 1.88
The surgical margin in soft-tissue sarcoma. J Bone Joint Surg Am (1989) 1.86
Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. Eur J Cancer (1997) 1.84
Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res (2001) 1.77
Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem (1997) 1.76
Clinical recognition of early invasive malignant melanoma. BMJ (1990) 1.75
Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int J Cancer (1979) 1.75
The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol (1985) 1.75
Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend (2001) 1.70
Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol (2006) 1.69
Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer (1995) 1.68
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer (1993) 1.64
TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol (1998) 1.63
Sunbeds in current use in Scotland: a survey of their output and patterns of use. Br J Dermatol (1998) 1.62
Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin Oncol (R Coll Radiol) (2012) 1.62
Adult paratesticular sarcomas: a review of 21 cases. J Urol (1991) 1.59
Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med (1999) 1.59
Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer (1991) 1.58
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol (1999) 1.54
Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia. Br Med J (1973) 1.50
Specificity of cell-mediated cytotoxicity against human melanoma lines: evidence for "non-specific" killing by activated T-cells. Int J Cancer (1975) 1.48
Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric (2011) 1.47
Cutaneous malignancy in males treated with photochemotherapy. Lancet (1990) 1.44
Serum lipid elevation during isotretinoin therapy for acne in the west of Scotland. Br J Dermatol (1990) 1.44
A CD56-negative case of blastic natural killer-cell lymphoma (agranular CD4+/CD56+ haematodermic neoplasm). Br J Dermatol (2004) 1.43
Fluorescent lights, ultraviolet lamps, and risk of cutaneous melanoma. BMJ (1988) 1.41
Immunosuppression in the treatment of inflammatory bowel disease. I. Changes in lymphoid sub-populations in the blood and rectal mucosa following cessation of treatment with azathioprine. Clin Exp Immunol (1974) 1.39
Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res (2001) 1.39
Primary excision margins and sentinel lymph node biopsy in clinically node-negative melanoma of the trunk or extremities. Clin Oncol (R Coll Radiol) (2011) 1.39
Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer (1995) 1.38
The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group. Ann Oncol (2001) 1.38
Use of monoclonal antibodies (UCHL1, Ki-B3) against T and B cell antigens in routine paraffin-embedded skin biopsy specimens. J Am Acad Dermatol (1989) 1.38
Oxygen wastage from anaesthetic machines. Anaesthesia (2007) 1.38
Immunological effects of solarium exposure. Lancet (1983) 1.38
Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol (2000) 1.37
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.36
Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer (1994) 1.35
Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet (1984) 1.34
Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol (2009) 1.32
A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. Addiction (1999) 1.32
Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett (2000) 1.31
Substance use among young people: the relationship between perceived functions and intentions. Addiction (1999) 1.30
Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.30
Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet (1999) 1.28
Mucinous carcinoma of the breast. A clinicopathologic, histochemical, and immunocytochemical study with special reference to neuroendocrine differentiation. Am J Surg Pathol (1994) 1.28
The helix-loop-helix protein Id-1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to reactivate DNA synthesis in senescent human fibroblasts. Dev Genet (1996) 1.27
Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol (2013) 1.27
Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood (2000) 1.27
Outcome and prognostic factors in soft tissue sarcoma in the adult. Int J Radiat Oncol Biol Phys (1993) 1.26
Staging of cutaneous melanoma. Ann Oncol (2009) 1.26
Role of intermolecular interactions on the electronic and geometric structure of a large pi-conjugated molecule adsorbed on a metal surface. Phys Rev Lett (2008) 1.26
An analysis of a melanoma epidemic. Int J Cancer (1993) 1.25
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis (2010) 1.25
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res (2003) 1.24
Early diagnosis of infantile seborrhoeic dermatitis and atopic dermatitis--total and specific IgE levels. Br J Dermatol (1983) 1.24
Economic burden of drug dependency. Social costs incurred by drug users at intake to the National Treatment Outcome Research Study. Br J Psychiatry (1998) 1.24
Previous pregnancy as a protective factor against death from melanoma. Lancet (1977) 1.23
Low natural-killer-cell activity in familial melanoma patients and their relatives. Br J Cancer (1979) 1.22
Granular cell tumor of the breast: a rare lesion resembling breast cancer. Eur J Gynaecol Oncol (2002) 1.22
An aid to the preoperative assessment of pigmented lesions of the skin. Br J Dermatol (1971) 1.21
Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care (2002) 1.20
Temozolomide induces senescence but not apoptosis in human melanoma cells. Br J Cancer (2007) 1.20
Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol (1997) 1.20
Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491). Int J Cancer (1995) 1.20
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol (2010) 1.20
Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood (1997) 1.19
Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol (2009) 1.18
Replicative senescence, aging and growth-regulatory transcription factors. Biol Signals (1997) 1.18
Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol (2000) 1.17
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet (2001) 1.17
Lymphocyte-dependent cytotoxic antibody activity against human transplantation antigens. Transplantation (1973) 1.17
Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. Virology (2012) 1.16
Is Apaf-1 expression frequently abrogated in melanoma? Cell Death Differ (2005) 1.15